US 8,552,002 · Application 11/570,983 · Granted Oct 8, 2013
US 8,552,002
Compounds and compositions as protein kinase inhibitors
Estimated expiration
August 25, 2029
2y 342d remaining
- Could not fetch continuity data for application PCTEP2005006815: Resource not found (404)
Earliest effective filing
Jun 23, 2005
+ 20 years
Jun 23, 2025
PTA +1524d
Aug 25, 2029
No TD
—
Final
Aug 25, 2029
This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included.
Calculation details
Base term
- Filing date
- October 15, 2008
- Earliest effective filing
- June 23, 2005
- Issue date
- October 8, 2013
- PTA
- +1524 days
- Base expiry (before PTA)
- June 23, 2025
June 23, 2005 + 20 years = June 23, 2025 + 1524 PTA days = August 25, 2029
- National stage entry of application PCTEP2005006815, filed Jun 23, 2005
- PRO60/582,425 — Provisional — not used for base term
Terminal disclaimers
Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated
The prosecution record for your AI
Application 11/570,983 · US 8,552,002
You have the date. Your AI can have the file.
PatentReply compiles the prosecution history behind US 8,552,002: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.
One public application a month is free. The first compile takes a few minutes.
Strategy and filing changes require your approval.
Permanent link
www.patentreply.ai/tools/patent-expiration/US8552002Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.